

# Amparo Larrauri

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3211375/amparo-larrauri-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65  
papers

3,108  
citations

22  
h-index

55  
g-index

77  
ext. papers

4,163  
ext. citations

9.6  
avg, IF

4.53  
L-index

#	Paper	IF	Citations
65	Regional excess mortality during the 2020 COVID-19 pandemic in five European countries.. <i>Nature Communications</i> , <b>2022</b> , 13, 482	17.4	8
64	Perimeter confinements of basic health zones and COVID-19 incidence in Madrid, Spain.. <i>BMC Public Health</i> , <b>2022</b> , 22, 216	4.1	1
63	Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data.. <i>PLoS Computational Biology</i> , <b>2022</b> , 18, e1009964	5	1
62	The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab159	1	5
61	No effect modification of influenza virus vaccine effectiveness by age or chronic condition was observed in the 2010/11 to 2017/18 seasons. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 1411-1419 <sup>26</sup>		
60	Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. <i>Eurosurveillance</i> , <b>2021</b> , 26,	19.8	21
59	Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries. <i>Influenza and Other Respiratory Viruses</i> , <b>2021</b> , 15, 732-741	5.6	4
58	Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. <i>Eurosurveillance</i> , <b>2021</b> , 26,	19.8	11
57	Real-time monitoring shows substantial excess all-cause mortality during second wave of COVID-19 in Europe, October to December 2020. <i>Eurosurveillance</i> , <b>2021</b> , 26,	19.8	33
56	The Impact of COVID-19 on Mortality in Spain: Monitoring Excess Mortality (MoMo) and the Surveillance of Confirmed COVID-19 Deaths.. <i>Viruses</i> , <b>2021</b> , 13,	6.2	1
55	Understanding influenza vaccination among Portuguese elderly: the social ecological framework. <i>Health Promotion International</i> , <b>2020</b> , 35, 1427-1440	3	2
54	Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine. <i>Influenza and Other Respiratory Viruses</i> , <b>2020</b> , 14, 302-310	5.6	5
53	Alternating patterns of seasonal influenza activity in the WHO European Region following the 2009 pandemic, 2010-2018. <i>Influenza and Other Respiratory Viruses</i> , <b>2020</b> , 14, 150-161	5.6	3
52	Illness Severity in Hospitalized Influenza Patients by Virus Type and Subtype, Spain, 2010-2017. <i>Emerging Infectious Diseases</i> , <b>2020</b> , 26, 220-228	10.2	4
51	Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. <i>Eurosurveillance</i> , <b>2020</b> , 25,	19.8	18
50	Transmissibility of influenza during the 21st-century epidemics, Spain, influenza seasons 2001/02 to 2017/18. <i>Eurosurveillance</i> , <b>2020</b> , 25,	19.8	2
49	Excess all-cause mortality during the COVID-19 pandemic in Europe - preliminary pooled estimates from the EuroMOMO network, March to April 2020. <i>Eurosurveillance</i> , <b>2020</b> , 25,	19.8	114

48	First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. <i>Eurosurveillance</i> , <b>2020</b> , 25,	19.8	310
47	Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. <i>BMJ, The</i> , <b>2020</b> , 371, m4509	5.9	73
46	Evaluating the impact of the weather conditions on the influenza propagation. <i>BMC Infectious Diseases</i> , <b>2020</b> , 20, 265	4	6
45	Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016-17 and 2017-18). <i>Vaccine: X</i> , <b>2019</b> , 3, 100042	3.8	14
44	European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?. <i>Clinical Microbiology and Infection</i> , <b>2019</b> , 25, 1266-1276	9.5	50
43	Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. <i>Eurosurveillance</i> , <b>2019</b> , 24,	19.8	41
42	Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the Netherlands: 2015/16 to 2017/18 influenza seasons. <i>Eurosurveillance</i> , <b>2019</b> , 24,	19.8	3
41	Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort. <i>Eurosurveillance</i> , <b>2019</b> , 24,	19.8	22
40	Co-circulation of influenza A(H1N1)pdm09 and influenza A(H3N2) viruses, World Health Organization (WHO) European Region, October 2018 to February 2019. <i>Eurosurveillance</i> , <b>2019</b> , 24,	19.8	12
39	Determinants of Fatal Outcome in Patients Admitted to Intensive Care Units With Influenza, European Union 2009-2017. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz462	1	14
38	Impact of Rapid On-demand Molecular Diagnosis of Pediatric Seasonal Influenza on Laboratory Workflow and Testing Costs: A Retrospective Study. <i>Pediatric Infectious Disease Journal</i> , <b>2019</b> , 38, 559-563	2.4	2
37	Impact of national influenza vaccination strategy in severe influenza outcomes among the high-risk Portuguese population. <i>BMC Public Health</i> , <b>2019</b> , 19, 1690	4.1	2
36	Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I-MOVE multicentre test-negative case-control study, 2011/2012-2016/2017. <i>Influenza and Other Respiratory Viruses</i> , <b>2018</b> , 12, 567-581	5.6	15
35	Estimating the burden of seasonal influenza in Spain from surveillance of mild and severe influenza disease, 2010-2016. <i>Influenza and Other Respiratory Viruses</i> , <b>2018</b> , 12, 161-170	5.6	33
34	Exploring the risk of severe outcomes and the role of seasonal influenza vaccination in pregnant women hospitalized with confirmed influenza, Spain, 2010/11-2015/16. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200934	3.7	11
33	Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively. <i>Eurosurveillance</i> , <b>2018</b> , 23,	19.8	44
32	Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016. <i>Eurosurveillance</i> , <b>2018</b> , 23,	19.8	48
31	Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. <i>Lancet, The</i> , <b>2018</b> , 391, 1285-1300	40	1109

30	2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. <i>Influenza and Other Respiratory Viruses</i> , <b>2018</b> , 12, 423-437	5.6	21
29	Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. <i>Eurosurveillance</i> , <b>2018</b> , 23,	19.8	43
28	Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza. <i>Vaccine</i> , <b>2017</b> , 35, 4298-4306	4.1	17
27	Climatic Factors and Influenza Transmission, Spain, 2010-2015. <i>International Journal of Environmental Research and Public Health</i> , <b>2017</b> , 14,	4.6	17
26	Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain. <i>PLoS ONE</i> , <b>2017</b> , 12, e0179160	3.7	14
25	Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017. <i>Eurosurveillance</i> , <b>2017</b> , 22,	19.8	79
24	2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. <i>Eurosurveillance</i> , <b>2017</b> , 22,	19.8	20
23	Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season. <i>Eurosurveillance</i> , <b>2017</b> , 22,	19.8	21
22	I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?. <i>Eurosurveillance</i> , <b>2016</b> , 21,	19.8	65
21	Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. <i>Eurosurveillance</i> , <b>2016</b> , 21, pii=30139	19.8	59
20	Waning protection of influenza vaccine against mild laboratory confirmed influenza A(H3N2) and B in Spain, season 2014-15. <i>Vaccine</i> , <b>2016</b> , 34, 2371-7	4.1	18
19	Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014. <i>Vaccine</i> , <b>2015</b> , 33, 3276-80	4.1	14
18	Influenza surveillance in Europe: comparing intensity levels calculated using the moving epidemic method. <i>Influenza and Other Respiratory Viruses</i> , <b>2015</b> , 9, 234-46	5.6	53
17	Higher vaccine effectiveness in seasons with predominant circulation of seasonal influenza A(H1N1) than in A(H3N2) seasons: test-negative case-control studies using surveillance data, Spain, 2003-2011. <i>Vaccine</i> , <b>2014</b> , 32, 4404-4411	4.1	14
16	Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination. <i>BMC Infectious Diseases</i> , <b>2013</b> , 13, 441	4	40
15	Epidemiology of the 2009 influenza pandemic in Spain. The Spanish Influenza Surveillance System. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2012</b> , 30 Suppl 4, 2-9	0.9	20
14	Influenza-related mortality in Spain, 1999-2005. <i>Gaceta Sanitaria</i> , <b>2012</b> , 26, 325-9	2.2	22
13	Oseltamivir-resistant pandemic influenza a (H1N1) 2009 viruses in Spain. <i>Journal of Clinical Virology</i> , <b>2011</b> , 51, 205-8	14.5	5

12	Influenza pandemic (H1N1) 2009 activity during summer 2009. Effectiveness of the 2008-9 trivalent vaccine against pandemic influenza in Spain. <i>Gaceta Sanitaria</i> , <b>2011</b> , 25, 23-8	2.2	11
11	Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010. <i>BMC Public Health</i> , <b>2011</b> , 11, 899	4.1	19
10	I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. <i>PLoS ONE</i> , <b>2011</b> , 6, e27622	3.7	79
9	Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network--pilot case-control studies using different control groups, 2008-2009 season, Spain. <i>Vaccine</i> , <b>2010</b> , 28, 2903-7	4.1	30
8	Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project. <i>European Journal of Pediatrics</i> , <b>2010</b> , 169, 997-1008	4.1	49
7	A surveillance network for meningococcal disease in Europe. <i>FEMS Microbiology Reviews</i> , <b>2007</b> , 31, 27-36	5.1	118
6	Impact of flu on hospital admissions during 4 flu seasons in Spain, 2000-2004. <i>BMC Public Health</i> , <b>2007</b> , 7, 197	4.1	15
5	Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. <i>Vaccine</i> , <b>2005</b> , 23, 4097-100	4.1	115
4	Influenza coverages in Spain and vaccination-related factors in the subgroup aged 50-64 years. <i>Vaccine</i> , <b>2003</b> , 21, 3550-5	4.1	23
3	S-adenosyl-L-methionine reverses the cholestatic effect of ethinylestradiol in rat hepatocytes by increasing its catabolism. <i>Cell Biology and Toxicology</i> , <b>1992</b> , 8, 13-26	7.4	3
2	Resistance of microalgae to modern water contaminants as the result of rare spontaneous mutations		2
1	Infection fatality risk for SARS-CoV-2: a nationwide seroepidemiological study in the non-institutionalized population of Spain		20